Quotient Clinical Extends Spray Drying Capabilities

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-04-2016
Volume 11
Issue 5

Quotient Clinical has expanded its clinical spray drying capability through the acquisition of a Niro Mobile Minor Spray Dryer.

Quotient Clinical, the Translational Pharmaceutics Company, has expanded its clinical spray drying capability through the acquisition of a Niro Mobile Minor Spray Dryer, according to an April 12, 2016 press announcement. Quotient develops spray-dried dispersions to overcome drug compound solubility issues, and the addition of a larger-scale spray dryer will allow the production of a range of batch sizes, up to two kilograms.

Located at Quotient’s new GMP facility at MediCity in Nottingham, UK-which is scheduled to open later in 2016-this expansion is a direct response to customer requests for ongoing product development support, including toxicology and later-stage clinical studies, Quotient said in a press announcement.

“Poor solubility is increasingly prevalent in drug pipelines across the industry,” said Nikki Whitfield, vice-president of Pharmaceutical Sciences. “We have established a broad suite of formulation approaches within our Translational Pharmaceutics platform to address these complex solubility and bioavailability challenges, and this latest investment will allow us to efficiently scale up the production of optimized formulations to support our clients’ downstream clinical development programs.”

Source: Quotient Clinical

 

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content